awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Table
SPARQL
Graphs
1
1
Services
1
1
Assets
0
0
Insights
Schema
BETA
Class frequency
Class hierarchy
Q37613320-05CD0DFE-F317-415B-8B55-EA79916C173C
Q37613320-05CD0DFE-F317-415B-8B55-EA79916C173C
BestRank
Statement
http://www.wikidata.org/entity/statement/Q37613320-05CD0DFE-F317-415B-8B55-EA79916C173C
Phase II study of an AKT inhibitor MK2206 in patients with relapsed or refractory lymphoma.
P2860
Q37613320-05CD0DFE-F317-415B-8B55-EA79916C173C
BestRank
Statement
http://www.wikidata.org/entity/statement/Q37613320-05CD0DFE-F317-415B-8B55-EA79916C173C
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
d2b5b88c0dd6826b3774e5b7e3829562fa93a606
P2860
A multicenter phase II trial (SAKK 36/06) of single-agent everolimus (RAD001) in patients with relapsed or refractory mantle cell lymphoma.